Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: October 7, 2025
Reporting Period: Third Quarter 2025 (referenced in press release)
Business Focus: Developer of the CyPath® Lung diagnostic test for lung cancer.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This 8-K serves as a notification of a corporate event rather than a financial statement.
Material Changes
- Sales Milestone: Sales of the CyPath® Lung diagnostic test reached a new high during the third quarter of 2025.
Guidance, Outlook, and Management Commentary
Management Commentary: The company issued a press release (Exhibit 99.1) announcing the sales record for its primary diagnostic product. No specific forward-looking guidance, risk factors, or contingencies are detailed within the body of this 8-K filing.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific sales volume figures and the magnitude of the increase.
- Verify the definition of "sales" used (e.g., units sold vs. revenue recognized).
- Check subsequent filings (10-Q or 10-K) for the financial impact of this sales increase on the company's overall liquidity and profitability.
- Confirm the current trading status of Common Stock (BIAF) and Warrants (BIAFW) on the Nasdaq Capital Market.